EUVIMEDEUVIMED entdecken
Crossref

Subjective Changes in Vision of Patients with Diabetic Macular Edema Treated with Ranibizumab

Anna Tarková, Kristína Ivkovičová, Zuzana Urbanová, Libor Hejsek, Jan Studnička

Czech and Slovak Ophthalmology · 11.11.2025

DOI: 10.31348/2025/43 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Czech and Slovak Ophthalmology, online erschienen am 11.11.2025. Verfasst von Anna Tarková und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Ranibizumab, Macular Edema, Diabetic Retinopathy, Angiogenesis Inhibitors.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate changes in the subjective perception of visual acuity in everyday life during intravitreal ranibizumab treatment in patients with diabetic macular edema using the Slovak version of the international NEI VFQ-25 questionnaire. Material and Methods: In a prospective study, 48 eyes of 30 treatment-naive patients were evaluated, and met the indication criteria. We determined best-corrected visual acuity in letter score (LS), intraocular pressure (IOP), central retinal thickness (CRT) and total macular volume (TMV). Patients received the NEI VFQ-25 questionnaire before the first and then after three, six and twelve months of treatment.

Results

Before treatment, LS averaged 68.1 letters, IOP 17.6 mmHg, CRT 480.5 μm, and TMV 11.2 mm3. After twelve months of intravitreal treatment, LS averaged 72.6 letters, IOP 17.0 mmHg, CRT 332.4 μm, and TMV 9.3 mm3. Comparison of data relating to subjective perception of vision before and after twelve months of treatment: perception of general health improved by 7%, vision in general improved by 15%, eye pain decreased by 8%, near vision improved by 12%, distance activities improved by 5%, social functioning improved by 4%, mental health improved by 6%, difficulties with functioning improved by 16%, dependency improved by 1%, driving improved by 2%, color vision improved by 7%, and peripheral vision improved by 9%.

Conclusion

We determined that anti-VEGF ranibizumab treatment improved objective parameters after one year of intravitreal therapy in LS, CRT and TMV. Subjective changes in visual perception improved in all the monitored parameters after one year of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RanibizumabMacular EdemaDiabetic RetinopathyAngiogenesis InhibitorsVisual AcuityAntibodies, Monoclonal, HumanizedHumansIntravitreal InjectionsFemaleMiddle AgedMaleAgedProspective Studies

Stichwörter der Autor:innen

diabetic macular edemaendothelial growth factor blockersranibizumab (Lucentis)subjective changes in vision

Substanzen

RanibizumabAngiogenesis InhibitorsAntibodies, Monoclonal, Humanized

Zitieren

APA

Tarková, A., Ivkovičová, K., Urbanová, Z., Hejsek, L., & Studnička, J. (2025). Subjective Changes in Vision of Patients with Diabetic Macular Edema Treated with Ranibizumab. Czech and Slovak Ophthalmology. https://doi.org/10.31348/2025/43

Vancouver

Tarková A, Ivkovičová K, Urbanová Z, Hejsek L, Studnička J. Subjective Changes in Vision of Patients with Diabetic Macular Edema Treated with Ranibizumab. Czech and Slovak Ophthalmology. 2025. doi:10.31348/2025/43

BibTeX
@article{Tarkov2025,
  author = {Tarková, Anna and Ivkovičová, Kristína and Urbanová, Zuzana and Hejsek, Libor and Studnička, Jan},
  title = {Subjective Changes in Vision of Patients with Diabetic Macular Edema Treated with Ranibizumab},
  journal = {Czech and Slovak Ophthalmology},
  year = {2025},
  doi = {10.31348/2025/43}
}
Kostenlos starten →